Anxo Pharmaceutical Co., Ltd. (TPEX:6677)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
16.60
0.00 (0.00%)
Aug 19, 2026, 1:36 PM CST

Anxo Pharmaceutical Balance Sheet

Millions TWD. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
323.91363.37358.92295.43241.32214.18
Short-Term Investments
10.91-2.2389.75--
Cash & Short-Term Investments
334.82363.37361.14385.18241.32214.18
Cash Growth
6.52%0.62%-6.24%59.61%12.67%3.09%
Accounts Receivable
205.14178.62210.5249.71240.86208.64
Other Receivables
15.329.054.6711.3610.6310.42
Receivables
220.46187.67215.17261.07251.49219.07
Inventory
259.98253.82262.42283.86243.1238.88
Prepaid Expenses
29.7818.9218.1522.1914.8817.11
Other Current Assets
0.6424.1621.6925.9920.715.54
Total Current Assets
845.68847.94878.56978.29771.5704.78
Property, Plant & Equipment
997.411,0221,0381,0791,1101,140
Long-Term Investments
57.7857.7852.5630--
Goodwill
-36.6136.6136.6136.6136.61
Other Intangible Assets
43.167.869.843.774.954.3
Long-Term Deferred Tax Assets
48.4444.2234.3822.0318.7511.77
Other Long-Term Assets
87.2350.4257.868.8232.7921.81
Total Assets
2,0802,0672,1082,2191,9741,919

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
75.2264.9581.5579.6994.0378.43
Accrued Expenses
-83.0588.4375.3571.5866.73
Short-Term Debt
305268205215256.38215
Current Portion of Long-Term Debt
54.6758.663.4658.557.5564.68
Current Portion of Leases
12.4513.629.3614.6511.58.69
Current Income Taxes Payable
---6.686.764.33
Current Unearned Revenue
28.7321.620.075.4314.475.04
Other Current Liabilities
108.8229.6734.7631.4242.829.95
Total Current Liabilities
584.87539.48502.61486.72555.07472.84
Long-Term Debt
367.42388.8437.61480.7528.08572.61
Long-Term Leases
1.935.9511.21933.5721.49
Long-Term Unearned Revenue
15.0616.416.2127.7326.4918.09
Long-Term Deferred Tax Liabilities
0.050.16----
Other Long-Term Liabilities
9.287.910.581.191.262.02
Total Liabilities
978.62958.7968.211,0151,1441,087

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
560.39558.71558.14556.64481.64481.64
Additional Paid-In Capital
426.72459.35483.68478.85211.08206.62
Retained Earnings
-6.59-34.13-25.4654.0132.1444.7
Comprehensive Income & Other
67.836---
Total Common Equity
986.52991.761,0221,089724.86732.96
Minority Interest
114.58116.37117113.76104.7898.99
Shareholders' Equity
1,1011,1081,1391,203829.64831.94
Total Liabilities & Equity
2,0802,0672,1082,2191,9741,919

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
741.46734.97726.63787.84887.09882.47
Net Cash (Debt)
-406.64-371.6-365.49-402.66-645.76-668.29
Net Cash Growth
------
Net Cash Per Share
-7.37-6.65-6.56-7.81-13.41-13.78
Filing Date Shares Outstanding
54.9355.8755.8155.6648.1648.16
Total Common Shares Outstanding
54.9355.8755.8155.6648.1648.16
Working Capital
260.81308.45375.94491.57216.43231.93
Book Value Per Share
17.9617.7518.3219.5715.0515.22
Tangible Book Value
943.36947.28975.921,049683.3692.04
Tangible Book Value Per Share
17.1816.9517.4918.8514.1914.37
Land
-576.53576.53576.53576.53576.53
Buildings
-423.96417.99417.99416.05417.89
Machinery
-501.41463.03464.55434.6436.82
Construction In Progress
-5.919.88---
Leasehold Improvements
-14.515.93.992.0210.09